Skip to main content

Table 3 Baseline characteristics (n = 198 patients)

From: Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years

Female, n (%) 142 (71.7)
Age, years, median (IQR) 56.2 (44.6 to 66.5)
Body mass index (kg/m 2 ), median (IQR) 27.2 (24.0 to 30.8)
Current and former smoker, n (%) 107 (54.0)
Educational status, n (%)  
Primary/secondary school 79 (39.9)
University/technical or other tertiary education 74 (37.4)
Other* 45 (22.7)
Engaged in paid employment, n (%) 92 (46.5)
Duration of polyarthritis, weeks, median (IQR) 16 (12 to 27)
Rheumatoid factor positive, n (%) 124 (62.6)
Anti-cyclic citrullinated peptide positive, n (%) 109 (56.2)
Shared epitope positive, n (%) 119 (61.0)
DAS28-erythrocyte sedimentation rate, mean (SD) 5.5 (1.3)
Low disease-activity, n (%) 10 (5.1)
Moderate disease-activity, n (%) 63 (32.3)
High disease-activity, n (%) 122 (62.6)
Physician global assessment of disease activity, median (IQR) 54.0 (34.0 to 70.0)
Erosive disease, erosion score ≥1, n (%) 36 (23.5)
Sharp/van der Heijde score, median (IQR) 2.0 (0.0 to 7.0)
Modified health assessment questionnaire, median (IQR) 0.63 (0.25 to 1.13)
Pain VAS, median (IQR) 57.0 (30.5 to 75.0)
Fatigue VAS, median (IQR) 50.5 (23.0 to 69.0)
Patient global assessment of disease activity VAS, median (IQR) 49.0 (26.0 to 64.8)
Rheumatology attitudes index-helplessness subscale, median (IQR) 14.0 (10.0 to 18.3)
Rheumatoid arthritis quality of life score, median (IQR) 10.0 (5.7 to 15.0)
Started triple DMARD therapy at baseline, n (%) 175 (88.4)
  1. *Trade school or not recorded. DAS28, disease activity score in 28 joints; DMARD, disease modifying anti-rheumatic drug; Triple DMARD therapy = methotrexate + sulfasalazine + hydroxychloroquine; VAS, visual analogue scale score.